Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case, SSRI 43% Improvement Relative Risk Case, All 39% Fluvoxamine for COVID-19  Glebov et al.  Prophylaxis c19early.org Favors fluvoxamine Favors control

Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study

Glebov et al., BMC Medicine, doi:10.1186/s12916-023-02877-9 (date from preprint)
Dec 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
26th treatment shown to reduce risk in November 2021
 
*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 5,664 mental health patients in the UK, showing lower risk of COVID-19 cases with recent antidepressant prescriptions overall, and for the subset of patients receiving SSRIs.
risk of case, 43.0% lower, OR 0.57, p = 0.04, adjusted per study, 90 days, SSRI, RR approximated with OR.
risk of case, 39.0% lower, OR 0.61, p = 0.03, adjusted per study, 90 days, all antidepressants, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Glebov et al., 20 Dec 2022, retrospective, United Kingdom, peer-reviewed, 5 authors, study period 1 April, 2020 - 31 December, 2020. Contact: oleg.glebov@kcl.ac.uk.
This PaperFluvoxamineAll
Antidepressant drug prescription and incidence of COVID-19: a retrospective cohort study
Oleg O Glebov, Ph.D Christoph Mueller, Robert Stewart, Dag Aarsland, Gayan Perera
doi:10.1101/2022.12.15.22283507
Question Is there an association between prescription of antidepressants and incidence of COVID-19 in the general population? Findings In this retrospective cohort study of mental health outpatients with a recent (1-3 months) antidepressant prescription, there was a statistically significant 40% decrease in positive COVID-19 tests. This association was specifically observed for the most commonly prescribed antidepressant class, Selective Serotonin Reuptake Inhibitors, and remained when adjusted for socioeconomic parameters and physical health. Meaning Antidepressant prescription was associated with lower incidence of COVID-19 in the community, warranting further investigation as prophylactics in prospective clinical studies. .
Authors' Contributions
References
Boulware, Pullen, Bangdiwala, A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med, doi:10.1056/nejmoa2016638
Burns, Beevor, Lelliott, Health of the Nation Outcome Scales for elderly people (HoNOS 65+), Br J Psychiatry J Ment Sci, doi:10.1192/bjp.174.5.424
Glebov, Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2
Glebov, Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing, FEBS J, doi:10.1111/febs.15369
Hoertel, Sánchez-Rico, Vernet, Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry, doi:10.1038/s41380-021-01021-4
Honos, Healthy London Partnership
Lau, Horschitz, Berger, Bartsch, Schloss, Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons, FASEB J Off Publ Fed Am Soc Exp Biol, doi:10.1096/fj.07-095471
Lenze, Fluvoxamine for Early Treatment of Covid-19: A Fully-Remote, Randomized Placebo Controlled Trial
Lenze, Mattar, Zorumski, Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.22760
Liu, Ginn, Dejnirattisai, Reduced neutralization of SARS-CoV-2
Machado, Iskedjian, Ruiz, Einarson, Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials, Curr Med Res Opin, doi:10.1185/030079906X132415
Mahase, Covid-19: Where are we on vaccines and variants?, BMJ, doi:10.1136/bmj.n597
Mason, Pathogenesis of COVID-19 from a cell biology perspective, Eur Respir J, doi:10.1183/13993003.00607-2020
Oskotsky, Marić, Tang, Mortality Risk Among Patients With COVID-19
Parker, Desai, Marti, Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review, Lancet Glob Health, doi:10.1016/S2214-109X(21)00593-3
Perera, Broadbent, Callard, Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource, BMJ Open, doi:10.1136/bmjopen-2015-008721
Reis, Dos, Silva, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health, doi:10.1016/S2214-109X(21)00448-4
Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infect Dis, doi:10.1093/ofid/ofab050
Takahashi, Miyoshi, Otomo, Osada, Yamaguchi et al., Suppression of dynamin GTPase activity by sertraline leads to inhibition of dynamindependent endocytosis, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2009.11.067
Wouters, Shadlen, Salcher-Konrad, Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment, The Lancet, doi:10.1016/S0140-6736(21)00306-8
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit